Abstract Objective Headache after ventriculoperitoneal (VP) shunting is classically attributed to CSF over-drainage or shunt malfunction. We hypothesized that a subset of adults instead experience an occipital neuralgia-like pain syndrome (“Occipital Neuralgia”) from shunt hardware irritating the occipital nerves, and that these cases respond better to nerve-targeted treatments than to shunt revisions. Methods We retrospectively reviewed 2,223 adults who underwent first-time VP shunt placement between 2000 and 2025 at a tertiary center. Patients with post-shunt headache were identified and classified as Occipital Neuralgia if they had occipital-predominant, lancinating pain with focal tenderness over the valve or tract, short-term relief from diagnostic occipital nerve block, and no evidence of over-drainage, malfunction, or infection on work-up. Clinical features, management, and outcomes (nerve blocks, neuromodulation, shunt adjustments or revisions) were compared between Occipital Neuralgia and other post-shunt headaches. Results Among 2,223 adults who underwent VP shunt placement, 32 patients (1.44%) developed new, persistent post-shunt headaches not attributable to shunt malfunction, over-drainage, or infection. Of these, 24 patients (1.08% of the total cohort; 75% of chronic post-shunt headaches) met criteria for Occipital Neuralgia. These patients typically presented with occipital-predominant, lancinating pain, focal scalp tenderness over the shunt valve or tract, and absence of orthostatic features. Neuroimaging demonstrated normal or slit ventricles without signs of intracranial hypotension or other structural intracranial pathology. Most patients experienced substantial symptomatic improvement following nerve-targeted therapies, whereas shunt-directed interventions provided limited benefit once pressure-related causes were excluded. Conclusions Post-shunt occipital neuralgia is a recognizable, under-appreciated cause of headache after VP shunting. Early recognition of a focal occipital neuropathic phenotype and nerve-targeted therapy can yield meaningful relief and help avoid unwarranted shunt revisions. Prospective validation of diagnostic criteria and management pathways is needed.
Shemesh et al. (Wed,) studied this question.